Visão geral da empresa
A biotechnology enterprise, Immunome, Inc. specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics within the United States. The company's clinical asset portfolio includes Varegacestat, which functions as a gamma secretase inhibitor. This organization operates within the Healthcare sector, specifically in the Biotechnology industry, a field characterized by high capital requirements and significant research and development expenditures. As of the latest data, the company holds a market capitalization of $2.45 billion, generates annual revenue of $6.94 million, and employs 177 individuals. The disparity between the substantial market cap of $2.45 billion and the modest revenue of $6.94 million indicates that the company's valuation is primarily driven by the potential future value of its clinical pipeline rather than current operational profitability, reflecting a common positioning for early-stage biotechnology firms where investor expectations focus on future clinical milestones rather than immediate cash generation.
Saúde financeira
Immunome, Inc. reported a trailing twelve-month revenue of $6.94 million, a net income of -$212,394,000, and an EBITDA of -$211,647,008. The significant gap between the $6.94 million in revenue and the -$212,394,000 in net income reveals a cost structure dominated by substantial operating expenses, likely comprising extensive research and development costs and overhead necessary to advance clinical assets. The company generated free cash flow of -$133,619,624, indicating a net outflow of cash that limits immediate financial flexibility and necessitates reliance on existing cash reserves or external capital raises to fund operations. Analyzing the margins, the gross margin stands at 0.0%, the operating margin is -3084.8%, and the profit margin is 0.0%; these figures collectively suggest that the company has not yet achieved positive profitability on its sales, with operating losses significantly outpacing revenue generation. On the balance sheet, the company holds $653.48 million in cash against $3.85 million in debt, resulting in a debt-to-equity ratio of 0.61. This configuration demonstrates a highly conservative balance sheet where liquid assets vastly exceed liabilities, providing a robust buffer against operational losses. The current ratio of 14.69 indicates an extremely strong short-term liquidity position, suggesting the company can easily cover its current liabilities with its current assets without immediate distress. Finally, the return on equity is -52.1% and the return on assets is -29.0%, metrics that reveal management has not yet generated positive returns on the capital invested or assets held, a typical characteristic of pre-revenue biotechnology companies still in the investment phase of their lifecycle.
Avaliação de valorização
The valuation metrics present a challenging picture for traditional equity analysis, with a trailing P/E ratio of N/A and a forward P/E of -10.27. The absence of a trailing P/E due to negative earnings and the negative forward P/E imply that the market is pricing the stock based on future expectations of profitability rather than current or historical earnings performance. The price-to-book ratio is 3.87, which indicates that the market is valuing the company at a significant premium over its book value, reflecting high expectations for the commercial success of its pipeline assets. Alternative valuation metrics show a price-to-sales ratio of 353.69 and an EV/EBITDA of -8.53, suggesting that investors are willing to pay a multiple of revenue that is exceptionally high relative to sales, while the negative EV/EBITDA reinforces the lack of current earnings power in the valuation model. Regarding price volatility, the stock has a 52-week high of $27.65 and a 52-week low of $5.15. Without a specific current share price provided in the facts to calculate the exact percentage deviation, the stock price is confined within this wide range, illustrating significant intraperiod fluctuation. The beta of 2.14 explains that the stock's price volatility is more than double that of the broader market, indicating that the security is highly sensitive to market movements and carries elevated systematic risk for investors seeking stability.
Growth & Income
The revenue growth year-over-year is -100.0%, while earnings growth year-over-year is N/A. The revenue contraction of 100.0% implies a cessation of revenue generation or a complete restructuring of the business model, and the lack of earnings growth data is consistent with the company's non-profitable status. Since the company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not distribute income to shareholders. Consequently, the company reinvests all available earnings or relies on cash reserves entirely into growth initiatives such as clinical trials and asset development rather than paying dividends. The overall growth and income profile is defined by a lack of current revenue generation, negative growth rates, and an absence of dividend income, positioning the security strictly as a speculative investment based on future clinical potential rather than current financial performance or income generation.